Human VEGF QuantiGlo ELISA Kit

Name: Human VEGF QuantiGlo ELISA Kit
Brand: R&D Systems
SKU: QVE00B
Price: 715 USD

R&D Systems, Inc. a Bio-Techne Brand

Catalog # QVE00B

Citations (21)

Product Datasheet / COA / SDS

Catalog #

Availability

Size / Price

Qty

Setting the standard in quality research reagents

Key Product Details

Assay Length:	5.5 hours
Sample Type & Volume Required Per Well:	Cell Culture Supernates (50 uL), Serum (50 uL), EDTA Plasma (50 uL), Heparin Plasma (50 uL), Saliva (50 uL), Urine (50 uL)
Sample Types:	Cell Culture Supernates, Serum, EDTA Plasma, Heparin Plasma, Saliva, Urine
Sensitivity:	5.99 pg/mL
Assay Range:	6.4 - 20,000 pg/mL (Cell Culture Supernates, Serum, EDTA Plasma, Heparin Plasma, Saliva, Urine)
Human VEGF QuantiGlo ELISA Kit Summary:	The QuantiGlo Human VEGF Chemiluminescent Immunoassay is a 5.5 hour solid phase ELISA designed to measure VEGF₁₆₅ levels in cell culture supernates, serum, plasma, saliva, and urine. It contains Sf 21-expressed recombinant human VEGF₁₆₅ and antibodies raised against the recombinant protein. Results obtained for naturally occurring human VEGF and recombinant human VEGF₁₂₁ showed linear curves that were parallel to the standard curves obtained using the QuantiGlo kit standards. These results indicate that this kit can be used to determine relative mass values for natural human VEGF.

View Full Technical Details for Human VEGF QuantiGlo ELISA Kit

Product Specifications for Human VEGF QuantiGlo ELISA Kit

Measurement	Quantitative ELISA
Conjugate	HRP
Reactivity	Human
Specificity	Natural and recombinant human VEGF. This assay also recognizes recombinant human VEGF_165b.
Cross-reactivity	Cross-reactivity observed with 1 or more available related molecules. < 50% cross-species reactivity observed with species tested.
Interference	Interference observed with 1 or more available related molecules.

Precision

Intra-Assay Precision (Precision within an assay) Four samples of known concentration were tested on one plate to assess intra-assay precision

Inter-Assay Precision (Precision between assays) Four samples of known concentration were tested in separate assays to assess inter-assay precision

Cell Culture Supernates, Serum, EDTA Plasma, Heparin Plasma, Saliva

	Intra-Assay Precision				Inter-Assay Precision
Sample	1	2	3	4	1	2	3	4
n	20	20	20	20	20	20	20	20
Mean (pg/mL)	22.2	392	1857	13972	22.7	389	1843	13411
Standard Deviation	1.76	12.9	52.3	557	2	27.6	131	562
CV%	7.9	3.3	2.8	4	8.8	7.1	7.1	4.2

Urine

	Intra-Assay Precision				Inter-Assay Precision
Sample	1	2	3	4	1	2	3	4
n	20	20	20	20	20	20	20	20
Mean (pg/mL)	24.4	417	1999	14245	22.9	383	1823	12825
Standard Deviation	1.24	16	44.9	608	2.36	28.9	141	536
CV%	5.1	3.8	2.2	4.3	10.3	7.5	7.7	4.2

Recovery

The recovery of VEGF spiked to three different levels throughout the range of the assay in various matrices was evaluated.

Sample Type	Average % Recovery	Range %
Cell Culture Media (n=4)	103	95-113
EDTA Plasma (n=4)	104	98-110
Heparin Plasma (n=4)	104	96-111
Serum (n=4)	102	90-112
Urine (n=4)	99	90-106

Linearity

To assess the linearity of the assay, samples containing or spiked with high concentrations of VEGF in various matrices were diluted with Calibrator Diluent to produce samples with values within the dynamic range of the assay.

Scientific Data Examples for Human VEGF QuantiGlo ELISA Kit

	Human VEGF Chemiluminescent ELISA Cell Culture Supernate/Serum/Plasma/Saliva Standard Curve
	Human VEGF Chemiluminescent ELISA Urine Standard Curve

Preparation and Storage

Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Background: VEGF

Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult (1-3). It is a member of the PDGF family that is characterized by the presence of eight conserved cysteine residues in a cystine knot structure and the formation of antiparallel disulfide-linked dimers (4). Humans express alternately spliced isoforms of 121, 145, 165, 183, 189, and 206 amino acids (aa) in length (4). VEGF₁₆₅ appears to be the most abundant and potent isoform, followed by VEGF₁₂₁ and VEGF₁₈₉ (3, 4). Isoforms other than VEGF₁₂₁ contain basic heparin-binding regions and are not freely diffusible (4). Human VEGF₁₆₅ shares 88% aa sequence identity with corresponding regions of mouse and rat VEGF. VEGF is expressed in multiple cells and tissues including skeletal and cardiac muscle (5, 6), hepatocytes (7), osteoblasts (8), neutrophils (9), macrophages (10), keratinocytes (11), brown adipose tissue (12), CD34⁺ stem cells (13), endothelial cells (14), fibroblasts, and vascular smooth muscle cells (15). VEGF expression is induced by hypoxia and cytokines such as IL-1, IL-6, IL-8, oncostatin M, and TNF-alpha (3, 4, 9, 16). VEGF isoforms are differentially expressed during development and in the adult (3).

VEGF dimers bind to two related receptor tyrosine kinases, VEGF R1 (also called Flt-1) and VEGF R2 (Flk-1/KDR), and induce their homodimerization and autophosphorylation (3, 4, 7, 17, 18). These receptors have seven extracellular immunoglobulin-like domains and an intracellular split tyrosine kinase domain. They are expressed on vascular endothelial cells and a range of non-endothelial cells. Although VEGF affinity is highest for binding to VEGF R1, VEGF R2 appears to be the primary mediator of VEGF angiogenic activity (3, 4). VEGF165 also binds the semaphorin receptor, neuropilin-1, which promotes complex formation with VEGF R2 (19).

VEGF is best known for its role in vasculogenesis. During embryogenesis, VEGF regulates the proliferation, migration, and survival of endothelial cells (3, 4), thus regulating blood vessel density and size, but playing no role in determining vascular patterns. VEGF promotes bone formation through osteoblast and chondroblast recruitment and is also a monocyte chemoattractant (20-22). After birth, VEGF maintains endothelial cell integrity and is a potent mitogen for micro- and macro-vascular endothelial cells. In adults, VEGF functions mainly in wound healing and the female reproductive cycle (3). In diseased tissues, VEGF promotes vascular permeability. It is thus thought to contribute to tumor metastasis by promoting both extravasation and tumor angiogenesis (23, 24). Various strategies have been employed therapeutically to antagonize VEGF-mediated tumor angiogenesis (25). Circulating VEGF levels correlate with disease activity in autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus (26).

Item	Value
Long Name	Vascular Endothelial Growth Factor
Entrez Gene IDs	7422 (Human); 22339 (Mouse); 83785 (Rat); 281572 (Bovine); 403802 (Canine); 493845 (Feline); 30682 (Zebrafish)
Alternate Names	MVCD1, VAS, VEGF, VEGF-A, VEGFA, VEGFMGC70609, VPF, VPFvascular endothelial growth factor, Vascular permeability factor, Vasculotropin, vascular endothelial growth factor A

Citations for Human VEGF QuantiGlo ELISA Kit (21)

Showing 1 - 10 of 21 citations Showing All

Filter By:

Search Title:

Citations are publications that use Bio-Techne products. Selected citations for Human VEGF QuantiGlo ELISA Kit include:

Species: Human
Sample Types: Cell Lysates

J Fu et al. (2022-01-01), Regenerating glomerular metabolism and function by podocyte pyruvate kinase M2 in diabetic nephropathy JCI Insight, 0(0).
PMID: 35133981
Species: Human
Sample Types: Cell Culture Supernates

M Xie et al. (2017-01-01), MicroRNA-1 acts as a tumor suppressor microRNA by inhibiting angiogenesis-related growth factors in human gastric cancer Gastric Cancer, 0(0).
PMID: 28493075
Species: Human
Sample Types: Cell Culture Supernates

A Abrahamsso et al. (2017-01-01), Downregulation of tumor suppressive microRNAs in vivo in dense breast tissue of postmenopausal women Oncotarget, 8(54):92134-92142.
PMID: 29190903
Species: Human
Sample Types: Cell Culture Supernates

Bader A et al. (2015-01-01), Hypoxic Preconditioning Increases Survival and Pro-Angiogenic Capacity of Human Cord Blood Mesenchymal Stromal Cells In Vitro. PLoS ONE, 10(9):e0138477.
PMID: 26380983
Species: Human
Sample Types: Cell Culture Supernates

Lecce et al. (2014-01-01), Aging impairs VEGF-mediated, androgen-dependent regulation of angiogenesis. Mol Endocrinol, 28(9):1487-501.
PMID: 25058601
Species: Mouse
Sample Types: Tissue Homogenates

Leifler K et al. (2013-01-01), Inflammation induced by MMP-9 enhances tumor regression of experimental breast cancer. J Immunol, 190(8):4420-30.
PMID: 23509357
Species: Human
Sample Types: CSF

Gupta PK et al. (2011-01-01), Vascular endothelial growth factor-A (VEGF-A) and chemokine ligand-2 (CCL2) in Amyotrophic Lateral Sclerosis (ALS) patients. J Neuroinflammation, 8(1):47.
PMID: 21569455
Species: Human
Sample Types: Urine

Chambers SK et al. (2010-01-01), Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin. Cancer Res., 16(21):5320-8.
PMID: 21041183
Species: Human
Sample Types: Cell Culture Supernates

Carroll VA et al. (2008-01-01), Regulation of angiogenic factors by HDM2 in renal cell carcinoma. Cancer Res., 68(2):545-52.
PMID: 18199551
Species: Human
Sample Types: Serum

Etto L et al. (2008-01-01), Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma. Leuk. Lymphoma, 49(2):257-64.
PMID: 18231911
Species: Human
Sample Types: Cell Culture Supernates

Saarinen NM et al. (2008-01-01), Dietary lariciresinol attenuates mammary tumor growth and reduces blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats. Int. J. Cancer, 123(5):1196-204.
PMID: 18528864
Species: Human
Sample Types: Tissue Homogenates

Bendrik C et al. (2008-01-01), Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer in vivo. Cancer Res., 68(9):3405-12.
PMID: 18451168
Species: Human
Sample Types: Cell Culture Supernates

Anelli V et al. (2007-01-01), Sphingosine kinase 1 is up-regulated during hypoxia in U87MG glioma cells. Role of hypoxia-inducible factors 1 and 2. J. Biol. Chem., 283(6):3365-75.
PMID: 18055454
Species: Human
Sample Types: Serum

Kut C et al. (2007-01-01), Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br. J. Cancer, 97(7):978-85.
PMID: 17912242
Species: Human
Sample Types: Cell Culture Supernates

Sutton KM et al. (2007-01-01), Selective inhibition of MEK1/2 reveals a differential requirement for ERK1/2 signalling in the regulation of HIF-1 in response to hypoxia and IGF-1. Oncogene, 26(27):3920-9.
PMID: 17213817
Species: Human
Sample Types: Cell Culture Supernates

Chen Y et al. (2007-01-01), Very low density lipoprotein receptor, a negative regulator of the wnt signaling pathway and choroidal neovascularization. J. Biol. Chem., 282(47):34420-8.
PMID: 17890782
Species: Human
Sample Types: Cell Culture Supernates

Mueller BM (2006-01-01), Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231 cells via MAPK pathways. Biochem. Biophys. Res. Commun., 344(4):1263-70.
PMID: 16650817
Species: Human
Sample Types: Cell Culture Supernates

Carroll VA et al. (2006-01-01), Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res., 66(12):6264-70.
PMID: 16778202
Species: Rabbit
Sample Types: Cell Culture Supernates

Cartwright L et al. (2006-01-01), Dynamic contrast-enhanced MRI to quantify VEGF-enhanced tissue-engineered bladder graft neovascularization: pilot study. J Biomed Mater Res A, 77(2):390-5.
PMID: 16429423
Species: Human
Sample Types: BALF

Feltis BN et al. (2006-01-01), Increased vascular endothelial growth factor and receptors: relationship to angiogenesis in asthma. Am. J. Respir. Crit. Care Med., 173(11):1201-7.
PMID: 16528018
Species: Human
Sample Types: Tissue Homogenates

Li L et al. (2005-01-01), Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res., 65(16):7249-58.
PMID: 16103076

There are no citations that match your criteria.

Showing 1 - 10 of 21 citations Showing All

Product Documents for Human VEGF QuantiGlo ELISA Kit

Product Datasheets

Download Product Datasheets

COA

SDS

Download SDS